

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated September 27, 2024 (the “**Prospectus**”) issued by Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or to any person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended from time to time, (the “**U.S. Securities Act**”)) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions.

The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act), except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold (1) solely to QIBs in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, Morgan Stanley Asia Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it and on behalf of the Underwriters, may, to the extent permitted by applicable laws of Hong Kong or elsewhere, over-allocate H Shares or effect transactions with a view to stabilizing or maintaining the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it and may be discontinued at any time. Any such stabilization activity is required to be brought to an end within 30 days from the last date for lodging of applications under the Hong Kong Public Offering (which is Saturday, November 2, 2024). Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which begins on the Listing Date, and is expected to expire on Saturday, November 2, 2024, the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date (which is currently expected to be on Tuesday, October 8, 2024).

Taimei

太美医疗科技

Zhejiang Taimei Medical Technology Co., Ltd.

浙江太美醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

- Number of Offer Shares under the Global Offering** : 25,779,000 H Shares (taking into account the full exercise of the Offer Size Adjustment Option and subject to the Over-allotment Option)
- Number of Hong Kong Offer Shares** : 12,889,600 H Shares (as adjusted after reallocation and taking into account the full exercise of the Offer Size Adjustment Option)
- Number of International Offer Shares** : 12,889,400 H Shares (as adjusted after reallocation and taking into account the full exercise of the Offer Size Adjustment Option and subject to the Over-allotment Option)
- Final Offer Price** : HK\$13.00 per H Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565%
- Nominal value** : RMB1.00 per H Share
- Stock code** : 2576

*Joint Sponsors, Overall Coordinators,
Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*

Morgan Stanley  **CICC 中金公司**

Joint Bookrunners and Joint Lead Managers



Zhejiang Taimei Medical Technology Co., Ltd. / 浙江太美醫療科技股份有限公司
ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information

Stock code	2576
Stock short name	TAIMEI TECH
Dealings commencement date	October 8, 2024*

*see note at the end of the announcement

Price Information

Final Offer Price	HK\$13.00
Offer Price Range	HK\$10.00 – HK\$13.00
Offer Price Adjustment exercised	N/A

Offer Shares and Share Capital

Number of Offer Shares (after the full exercise of the Offer Size Adjustment Option)	25,779,000
Number of Offer Shares in Hong Kong Public Offering (after reallocation and the full exercise of the Offer Size Adjustment Option)	12,889,600
Number of Offer Shares in International Offering (after reallocation and the full exercise of the Offer Size Adjustment Option)	12,889,400
Number of issued Shares upon Listing (assuming the Over-allotment Option is not exercised)	563,779,000

Offer Size Adjustment Option (Upsize option)

Number of additional Shares issued under the option	3,362,400
- Hong Kong Public Offering	1,681,200
- International Offering	1,681,200

Note: The Offer Size Adjustment Option was exercised in full, pursuant to which the Company is issuing and allotting 3,362,400 additional H Shares, representing approximately 15.00% of the total number of Offer Shares initially available under the Global Offering, at the final Offer Price.

Over-allocation

Number of Offer Shares over-allocated	3,866,800
--	-----------

Note: Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.

Proceeds

Gross proceeds ^{Note 1}	HK\$335.1 million
---	-------------------

Less: Estimated listing expenses payable based on Final Offer Price	HK\$75.6 million ^{Note 2}
Net proceeds	HK\$259.5 million

Notes:

(1) Gross proceeds refers to the amount which the issuer is entitled receive, after taking into account the full exercise of the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.

(2) Includes HK\$28.1 million which had been incurred as of March 31, 2024. For details, please refer to the paragraph headed “Financial Information – Listing Expenses” in the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

Number of valid applications	25,455
Number of successful applications	7,799
Subscription level (before taking into account the full exercise of the Offer Size Adjustment Option)	156.33 times
Claw-back triggered	Yes
Number of Offer Shares initially available under the Hong Kong Public Offering	2,241,800
Number of Offer Shares reallocated from the International Offering (claw-back)	8,966,600
Final number of Offer Shares under the Hong Kong Public Offering (after reallocation and the full exercise of the Offer Size Adjustment Option)	12,889,600
% of final number of Offer Shares under the Hong Kong Public Offering to the Global Offering (after reallocation and the full exercise of Offer Size Adjustment Option)	Approximately 50%

Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

Number of places	150
Subscription level (before taking into account the full exercise of the Offer Size Adjustment Option)	2.58 times
Number of Offer Shares initially available under the International Offering	20,174,800
Number of Offer Shares reallocated to the Hong Kong Public Offering (claw-back)	8,966,600
Final number of Offer Shares under the International Offering (after reallocation and the full exercise of the Offer Size Adjustment Option)	12,889,400

% of final number of Offer Shares under the International Offering to the Global Offering (after reallocation and the full exercise of Offer Size Adjustment Option)	Approximately 50%
---	-------------------

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Allottee with waivers/consents obtained

Investor	No. of Offer Shares allocated^{Note 1}	% of Offer Shares (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)	% of total issued share capital after the Global Offering (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)	Relationship
China Southern Asset Management Co., Ltd (南方基金管理股份有限公司) (“Southern Asset Management”)	1,790,000	6.94%	0.32%	Each of Southern Asset Management and Huatai Financial Holdings (Hong Kong) Limited, a syndicate member of the Global Offering, is a member of the same group of companies.
Total	1,790,000	6.94%	0.32%	

Note:

(1) The allocation of Offer Shares to the above allottee is in compliance with all the conditions under the consent granted by the Stock Exchange. For details, please refer to the section headed “Others / Additional Information” in this announcement.

LOCK-UP UNDERTAKINGS

Controlling Shareholders

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
Mr. ZHAO Lu / 趙璐 (“ Mr. Zhao ”) ^{Notes 1 & 2}	93,042,388	-	16.50%	October 7, 2025 Note 3
Shanghai Xiaoju Enterprise Management Partnership (Limited Partnership) / 上海小橋企業管理合夥企業(有限合夥) (“ Shanghai Xiaoju ”) ^{Note 1}	20,312,190	-	3.60%	October 7, 2025 Note 3
Shanghai Kunrui Enterprise Management Partnership (Limited Partnership) / 上海昆銳企業管理合夥企業(有限合夥) (“ Shanghai Kunrui ”) ^{Note 1}	19,344,866	-	3.43%	October 7, 2025 Note 3
Xinyu Shenkong Enterprise Management Partnership (Limited Partnership) / 新余深空企業管理合夥企業(有限合夥) (“ Xinyu Shenkong ”) ^{Notes 1 & 2}	18,204,844	-	3.23%	October 7, 2025 Note 3
Xinyu Haolin Enterprise Management Partnership (Limited Partnership) / 新余浩霖企業管理合夥企業(有限合夥)	13,974,550	-	2.48%	October 7, 2025 Note 3

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
(“Xinyu Haolin”) Note 1				
Zhoushan Yijin Investment Management Partnership (Limited Partnership) / 舟山憶瑾投資管理合夥企業(有限合夥) (“Zhoushan Yijin”) Notes 1 & 2	5,380,538	-	0.95%	October 7, 2025 Note 3
Xinyu Qiwushi Medical Technology Partnership (Limited Partnership) / 新余七武士醫療科技合夥企業(有限合夥) (“Xinyu Qiwushi”) Note 1	3,620,740	-	0.64%	October 7, 2025 Note 3
Xinyu Taimei Xingmeng Enterprise Management Partnership (Limited Partnership) / 新余太美星盟企業管理合夥企業(有限合夥) (“Xinyu Xingmeng”) Note 1	2,433,000 (including 1,216,500 H Shares)	0.61%	0.43%	October 7, 2025 Note 3
Xinyu Ruansu Enterprise Management Partnership (Limited Partnership) / 新余軟素企業管理合夥企業(有限合夥) (“Ruansu”)	2,293,494	-	0.41%	October 7, 2025 Note 3

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
Enterprise Management) ^{Note 1}				
Xinyu Taimei Nuoming Enterprise Management Partnership (Limited Partnership) / 新余太美諾銘企業管理合夥企業(有限合夥) (“Xinyu Nuoming”) Note 1	812,918	-	0.14%	October 7, 2025 Note 3
Subtotal	179,419,528 (including 1,216,500 H Shares)	0.61%	31.82%	

Notes:

(1) Immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised), Mr. Zhao is able to exercise approximately 31.82% voting rights in the Company through (i) 93,042,388 Shares directly held by him, (ii) 62,791,758 Shares held by Shanghai Xiaoju, Shanghai Kunrui, Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming and Xinyu Xingmeng, each of which is a limited partnership established under the laws of the PRC and is managed by Mr. Zhao as its executive partner, (iii) 5,380,538 Shares held by Zhoushan Yijin which is a limited partnership established under the laws of the PRC and is managed by Mr. Zhao as its general partner, and (iv) 18,204,844 Shares held by Xinyu Shengkong which is a limited partnership established under the laws of the PRC and is managed by Mr. Zhao as its general partner.

(2) As at the date of this announcement, Ms. Tang held 95% partnership interest in Zhoushan Yijin and 99% partnership interest in Xinyu Shengkong as their respective sole limited partner. Therefore, Ms. Tang, Mr. Zhao and the entities as listed above constitute a group of Controlling Shareholders of the Company.

(3) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. In accordance with the relevant Listing Rules/guidance materials, the required lock-up for the first six-month period ends on April 7, 2025 and for the second six-month period ends on October 7, 2025.

Pre-IPO Investors (as defined in the Prospectus)

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings</i>
All Pre-IPO Investors Note 1	358,580,472 (including 173,597,033 H Shares)	86.54%	63.60%	October 7, 2025 Note 2
Subtotal	358,580,472 (including 173,597,033 H Shares)	86.54%	63.60%	

Notes:

(1) Please refer to the paragraph headed “History, Development and Corporate Structure — The Pre-IPO Investments — (5) Information about Our Pre-IPO Investors” in the Prospectus for the identities of the Pre-IPO Investors.

(2) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued)	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)
Top 1	3,866,800	30.0%	23.1%	15.0%	13.0%	3,866,800	0.7%	0.7%
Top 5	14,356,800	111.4%	85.7%	55.7%	48.4%	14,356,800	2.5%	2.5%
Top 10	16,259,000	126.1%	97.0%	63.1%	54.8%	16,259,000	2.9%	2.9%
Top 25	16,727,400	129.8%	99.8%	64.9%	56.4%	16,727,400	3.0%	2.9%

Note

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued)	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued H Shares capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)	Number of Shares held upon Listing
Top 1	-	-	-	-	-	30,061,593	15.0%	14.7%	53,970,546
Top 5	-	-	-	-	-	101,035,909	50.4%	49.4%	226,243,178
Top 10	-	-	-	-	-	154,136,128	76.8%	75.4%	323,641,678
Top 25	15,796,800	122.6%	94.3%	61.3%	53.3%	190,610,333	95.0%	93.2%	553,796,800

Note

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders *	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over- allotment Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over- allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised and new H Shares are issued)	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over- allotment Option is exercised and new H Shares are issued)
Top 1	-	-	-	-	-	1,216,500	179,419,528	31.8%	31.6%
Top 5	-	-	-	-	-	86,714,129	377,766,330	67.0%	66.5%
Top 10	-	-	-	-	-	146,878,673	487,847,642	86.5%	85.9%
Top 25	15,796,800	122.6%	94.3%	61.3%	53.3%	190,610,333	553,796,800	98.2%	97.6%

Note

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, 25,455 valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT / BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
POOL A			
200	9,549	257 out of 9,549 to receive 200 Shares	2.69%
400	1,694	91 out of 1,694 to receive 200 Shares	2.69%
600	1,533	123 out of 1,533 to receive 200 Shares	2.67%
800	797	85 out of 797 to receive 200 Shares	2.67%
1,000	1,438	191 out of 1,438 to receive 200 Shares	2.66%
1,200	259	41 out of 259 to receive 200 Shares	2.64%
1,400	197	36 out of 197 to receive 200 Shares	2.61%
1,600	294	61 out of 294 to receive 200 Shares	2.59%
1,800	150	34 out of 150 to receive 200 Shares	2.52%
2,000	1,403	353 out of 1,403 to receive 200 Shares	2.52%
3,000	1,690	638 out of 1,690 to receive 200 Shares	2.52%
4,000	585	294 out of 585 to receive 200 Shares	2.51%
5,000	393	246 out of 393 to receive 200 Shares	2.50%
6,000	268	201 out of 268 to receive 200 Shares	2.50%
7,000	452	395 out of 452 to receive 200 Shares	2.50%
8,000	284	200 Shares	2.50%
9,000	104	200 Shares plus 13 out of 104 to receive additional 200 Shares	2.50%
10,000	1,047	200 Shares plus 261 out of 1,047 to receive additional 200 Shares	2.50%
20,000	904	400 Shares plus 452 out of 904 to receive additional 200 Shares	2.50%
30,000	380	600 Shares plus 285 out of 380 to receive additional 200 Shares	2.50%
40,000	378	800 Shares plus 364 out of 378 to receive additional 200 Shares	2.48%

50,000	203	1,200 Shares plus 41 out of 203 to receive additional 200 Shares	2.48%
60,000	156	1,400 Shares plus 69 out of 156 to receive additional 200 Shares	2.48%
70,000	91	1,600 Shares plus 62 out of 91 to receive additional 200 Shares	2.48%
80,000	226	1,800 Shares plus 208 out of 226 to receive additional 200 Shares	2.48%
90,000	55	2,200 Shares plus 9 out of 55 to receive additional 200 Shares	2.48%
100,000	282	2,400 Shares plus 113 out of 282 to receive additional 200 Shares	2.48%
150,000	147	3,600 Shares plus 89 out of 147 to receive additional 200 Shares	2.48%
200,000	164	4,800 Shares plus 132 out of 164 to receive additional 200 Shares	2.48%
250,000	46	6,200 Shares	2.48%
300,000	37	7,400 Shares plus 8 out of 37 to receive additional 200 Shares	2.48%
350,000	63	8,600 Shares plus 30 out of 63 to receive additional 200 Shares	2.48%
	25,269	Total number of Pool A successful applicants: 7,613	
POOL B			
400,000	133	28,000 Shares plus 94 out of 133 to receive additional 200 Shares	7.04%
450,000	4	31,600 Shares plus 1 out of 4 to receive additional 200 Shares	7.03%
500,000	11	35,000 Shares plus 8 out of 11 to receive additional 200 Shares	7.03%
600,000	13	42,000 Shares plus 11 out of 13 to receive additional 200 Shares	7.03%
700,000	7	49,200 Shares	7.03%
800,000	3	56,200 Shares	7.03%
900,000	1	63,200 Shares	7.02%
1,000,000	4	70,000 Shares	7.00%
1,120,800	10	78,400 Shares plus 2 out of 10 to receive additional 200 Shares	7.00%

	186	Total number of Pool B successful applicants: 186
--	-----	---

As at the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHERS / ADDITIONAL INFORMATION

Placing with a prior consent under paragraph 5(1) of Appendix F1 to the Listing Rules (the "Placing Guidelines")

1,790,000 Offer Shares, representing approximately 6.94% of the total number of Offer Shares (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised) and approximately 0.32% of the total issued share capital after the Global Offering (after taking into account the Offer Size Adjustment Option and assuming the Over-allotment Option is not exercised) were placed to Southern Asset Management. Such Offer Shares will be held by Southern Asset Management on a discretionary basis. As at the date of this announcement, Huatai Securities Co., Ltd. (華泰證券股份有限公司) (a company listed on the Main Board of the Stock Exchange with the stock code: 6886) owned 45.00% of the equity interest in Southern Asset Management, and 100% of the equity interest in Huatai Financial Holdings (Hong Kong) Limited, a syndicate member of the Global Offering, respectively. Therefore, Southern Asset Management and Huatai Financial Holdings (Hong Kong) Limited are members of the same group pursuant to paragraph 13(7) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants.

Southern Asset Management, a qualified domestic institutional investor as approved by the relevant PRC authority to conduct asset management business, will hold the Offer Shares as the independent agent and discretionary manager of certain QDII funds. Each of such QDII funds is an independent third party of Southern Asset Management and Huatai Financial Holdings (Hong Kong) Limited and the companies which are members of the same group of Huatai Financial Holdings (Hong Kong) Limited.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to Southern Asset Management. The allocation of Offer Shares to Southern Asset Management is in compliance with all the conditions under the consent granted by the Stock Exchange.

Offer Size Adjustment Option

The Offer Size Adjustment Option has been exercised by the Company in full after consultation with the Overall Coordinators (for themselves and on behalf of the Underwriters), pursuant to which the Company

is issuing and allotting 3,362,400 additional H Shares, representing approximately 15.00% of the total number of Offer Shares initially available under the Global Offering, at the final Offer Price.

Accordingly, the total number of Offer Shares finally available under the Global Offering (after taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option) that would be allotted and issued by the Company is 25,779,000 H Shares and the total issued share capital of the Company upon Listing (after taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option) will be 563,779,000 Shares.

Reallocation

As the Hong Kong Public Offering has been over-subscribed by more than 100 times of the total number of Offer Shares initially available under the Hong Kong Public Offering, the reallocation procedure as disclosed in the paragraph headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus has been applied.

The number of Offer Shares initially available under the Hong Kong Public Offering is 2,241,800 H Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Offer Size Adjustment Option and the Over-allotment Option). As a result of such reallocation and the full exercise of the Offer Size Adjustment Option, the final number of Offer Shares under the Hong Kong Public Offering is adjusted to 12,889,600 H Shares, representing approximately 50% of the total number of Offer Shares available under the Global Offering (after taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option).

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential

investors should read the Prospectus for detailed information about the Global Offering described above before deciding whether or not to invest in the Shares thereby being offered.

**Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on October 8, 2024).*

PUBLIC FLOAT

Immediately following the completion of the Global Offering (after taking into account the full exercise of the Offer Size Adjustment Option and before the exercise of the Over-allotment Option), an aggregate of 186,398,182 H Shares or approximately 33.06% of the total issued share capital of the Company will be held in the public hands. Therefore, the number of H Shares in the public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering (after taking into account the full exercise of the Offer Size Adjustment Option and before the exercise of the Over-allotment Option), (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the Shares held in the public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, October 8, 2024 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, October 8, 2024 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, October 8, 2024 (Hong Kong time).

The H Shares will be traded in board lots of 200 H Shares each, and the stock code of the H Shares will be 2576.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Mr. Zhao Lu
Chairman of the Board and executive Director

Hong Kong, October 7, 2024

As at the date of this announcement, Directors are: (i) Mr. Zhao Lu, Mr. Ma Dong, Mr. Zhang Hongwei, Mr. Lu Yiming, Mr. Huang Yufei and Ms. Ni Xiaomei as executive Directors; and (ii) Dr. Jiang Xiao, Dr. Li Zhiguo and Mr. Fung Che Wai Anthony as independent non-executive Directors.